1027261-77-3

Upstream product

• 159547-20-3 3-Fluoro-4-methyl-2'-(N-t-butylsulfamoyl)biphenyl 
• 159547-21-4 [3-Fluoro-2'-(N-t-butylsulfamoyl)biphenyl-4-yl]methyl Bromide 
• 159547-23-6 2-(5-amino-2-bromophenyl)-4-[[2'-(N-t-butylsulfamoyl)-3-fluorobiphenyl-4-yl]methyl]-5-n-butyl-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 159547-22-5 2-(2-bromo-5-nitrophenyl)-5-n-butyl-4-<<2'-(N-tert-butylsulfamoyl)-3-fluorobiphenyl-4-yl>methyl>-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 150691-04-6 2-(tert-butylamino)sulfonylphenylboronic acid 
• 159547-14-5 2-(2-bromo-5-nitrophenyl)-5-n-butyl-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 100367-78-0 (2-bromo-5-nitrophenyl)hydrazine 
• 5133-68-6 ethyl N-carbethoxyvalerimidate 
• 51436-99-8 2-fluoro-4-bromotoluene 

Relevant academic research and scientific papers

Potent and orally active angiotensin II receptor antagonists with equal affinity for human AT1 and AT2 subtypes

In order to block the effects induced by the interactions between angiotensin II (AII) and both AT1 and AT2 receptors, we have pursued the discovery of orally active non-peptide AII antagonists that exhibit potent and equal affinity